Furthermore, it opens novel possibilities to establish protocols for the selective expansion of KIR-only NK cells, which are anticipated to be highly versatile for the detection and eradication of tumor cells with aberrant HLA class I expression and that are unaffected by tumor-mediated inhibition through the HLA-E-NKG2A axis. The gene discussed is KIR3DL1; the disease is neoplasm.